We now describe a novel PKC-activating compound, EBC-46, and demonstrate that a single intra-lesional injection is sufficient for enduring regression and ultimate cure of diverse tumor types in pre-clinical models of cancer. The gene discussed is PRRT2; the disease is cancer.